drugset / Trial / NCT00139698

Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

NCT00139698 ↗

Phase 3 Completed 410 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Timeline

Start
2005-09
Primary completion
—
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg —
Subject Hydrochlorothiazide Unknown 25 mg —
Subject olmesartan alone or in combination with hydrochlorothiazide Unknown 20 mg —
Subject olmesartan alone or in combination with hydrochlorothiazide Unknown 40 mg —